Search Results
You are looking at 1 - 2 of 2 items for
- Author or Editor: Chengcheng Liu x
- Refine by Access: All Content x
Abstract
Objective—To evaluate the effect of head position on intraocular pressure (IOP) in horses.
Animals—30 horses.
Procedures—Horses were sedated with detomidine HCl (0.01 mg/kg, IV). Auriculopalpebral nerve blocks were applied bilaterally with 2% lidocaine HCl. The corneas of both eyes were anesthetized with ophthalmic 0.5% proparacaine solution. Intraocular pressures were measured with an applanation tonometer with the head positioned below and above heart level. The mean of 3 readings was taken for each eye at each position for data analysis. The effect of head position on IOP was assessed and generalized estimating equations were used to adjust for the correlation from repeated measures of the same eye and intereye correlation from the same horse.
Results—Of the 60 eyes, 52 (87%) had increased IOP when measured below the heart level. A significant difference (mean ± SE, 8.20 ± 1.01 mm Hg) was seen in the mean IOP when the head was above (17.5 ± 0.8 mm Hg) or below (25.7 ± 1.2 mm Hg) heart level. No significant effect of sex, age, or neck length on IOP change was found.
Conclusions and Clinical Relevance—Head position has a significant effect on the IOP of horses. Failure to maintain a consistent head position between IOP measurements could potentially prevent the meaningful interpretation of perceived aberrations or changes in IOP.
Abstract
Objective—To determine effects of the topically applied calcium-channel blocker flunarizine on intraocular pressure (IOP) in clinically normal dogs.
Animals—20 dogs.
Procedures—Baseline diurnal IOPs were determined by use of a rebound tonometer on 2 consecutive days. Subsequently, 1 randomly chosen eye of each dog was treated topically twice daily for 5 days with 0.5% flunarizine. During this treatment period, diurnal IOPs were measured. In addition, pupillary diameter and mean arterial blood pressure (MAP) were evaluated. Serum flunarizine concentrations were measured on treatment day 5. Intraday fluctuation of IOP was analyzed by use of an ANOVA for repeated measures and a trend test. Changes in IOP from baseline values were assessed and compared with IOPs for the days of treatment. Values were also compared between treated and untreated eyes.
Results—A significant intraday fluctuation in baseline IOP was detected, which was highest in the morning (mean ± SE, 15.8 ± 0.63 mm Hg) and lowest at night (12.9 ± 0.61 mm Hg). After 2 days of treatment, there was a significant decrease in IOP from baseline values in treated (0.93 ± 0.35 mm Hg) and untreated (0.95 ± 0.34 mm Hg) eyes. There was no significant treatment effect on pupillary diameter or MAP. Flunarizine was detected in serum samples of all dogs (mean ± SD, 3.89 ± 6.36 μg/L).
Conclusions and Clinical Relevance—Topically applied flunarizine decreased IOP in dogs after 2 days of twice-daily application. This calcium-channel blocker could be effective in the treatment of dogs with glaucoma.
